- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01692366
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Primary Objective:
- To evaluate the efficacy of daily oral doses of 300 mg, 400 mg, and 500 mg SAR302503 and combined for the response rate defined with the ≥35% reduction of spleen volume as determined by magnetic resonance imaging (MRI or computed tomography scan [CT] in patients with contraindications for MRI).
Secondary Objectives:
- To evaluate the safety of SAR302503 for both pooled (300, 400, and 500mg) and individual doses population.
- To evaluate the pharmacokinetics (PK) of SAR302503 after single and repeat-dose.
- To evaluate the effect on Myelofibrosis (MF)-associated symptoms (Key MF symptoms) as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF).
- To evaluate the durability of splenic response.
- To evaluate the effect of SAR302503 on bone marrow with regard to changes on reticulin fibrosis.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Akita-Shi, Japan
- Investigational Site Number 392010
-
Bunkyo-Ku, Japan
- Investigational Site Number 392002
-
Bunkyo-Ku, Japan
- Investigational Site Number 392006
-
Sendai-Shi, Japan
- Investigational Site Number 392004
-
Shinjuku-Ku, Japan
- Investigational Site Number 392008
-
Shinjuku-Ku, Japan
- Investigational Site Number 392009
-
Suita-Shi, Japan
- Investigational Site Number 392003
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Diagnosis of primary or post-polycythemia vera or post-essential thrombocythemia myelofibrosis
- Myelofibrosis classified as high-risk or intermediate-risk level 2
- Enlarged spleen, palpable at least 5 cm below costal margin
- Active symptoms of myelofibrosis
- At least 20 years of age
- Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at study entry
- Absence of active malignancy other than myelofibrosis
- Written informed consent to participate.
Exclusion criteria:
- Splenectomy.
- Any recent chemotherapy (eg, hydroxyurea), immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), immunosuppressive therapy, corticosteroids >10 mg/day prednisone or equivalent, or growth factor treatment (eg, erythropoietin), hormones (eg, androgens, danazol) within 14 days prior to initiation of study drug.
- Major surgery therapy within 28 days or radiation including spleen radiation within 6 months prior to initiation of study drug.
- Concomitant treatment with or use of pharmaceutical or herbal agents known to be moderate or severe inhibitors or inducers CYP3A4.
- Active acute infection requiring antibiotics.
- Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
- Participation in any study of an investigational agent (drug, biologic, device) within 30 days, unless during nontreatment phase.
- Prior treatment with a JAK 2 Inhibitor.
- Treatment with aspirin in doses >150 mg/day
- Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness.
- Pregnant or lactating female. Once the lactating female stop and participate in the study, she cannot re-start feeding the baby.
- Women of childbearing potential, unless using effective contraception while on study drug. Otherwise patients must be post-menopausal (at least 1 years from last menstruation without other medical reason), or surgically sterile.
- Known active (acute or chronic) Hepatitis A, B, or C; and hepatitis B and C carriers.
- Prior history of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH])
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SAR302503 300mg
SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg.
SAR302503 will be taken on an empty stomach at approximately the same time each day
|
Pharmaceutical form:Capsule Route of administration: oral |
EXPERIMENTAL: SAR302503 400 mg
SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg.
SAR302503 will be taken on an empty stomach at approximately the same time each day
|
Pharmaceutical form:Capsule Route of administration: oral |
EXPERIMENTAL: SAR302503 500 mg
SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg.
SAR302503 will be taken on an empty stomach at approximately the same time each day
|
Pharmaceutical form:Capsule Route of administration: oral |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction as measured by MRI (or CT scan in subjects with contraindications for MRI). - Time Frame:
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with Serious Adverse events using NCI CTCAE v4.03, clinical parameters and vital signs
Time Frame: From baseline to the 30 days after last drug administration
|
From baseline to the 30 days after last drug administration
|
Measurements of SAR302503 pharmacokinetic endpoints including Cmax, Tmax, and AUC0-24
Time Frame: SAR302503, pre-dose and post-dose plasma collections will be obtained on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 2, and Cycle 3 Day 1
|
SAR302503, pre-dose and post-dose plasma collections will be obtained on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 2, and Cycle 3 Day 1
|
Symptom Response Rate (SRR): Proportion of subjects with a ≥50% reduction in the total symptom score using the modified MFSAF
Time Frame: 24 weeks
|
24 weeks
|
Duration of maintenance of ≥35% reduction in spleen volume
Time Frame: From baseline to the 30 days after last drug administration
|
From baseline to the 30 days after last drug administration
|
Percent change from baseline in spleen volume measured by MRI
Time Frame: 24 weeks
|
24 weeks
|
Percent change from baseline in spleen size measured by palpation
Time Frame: 24 weeks
|
24 weeks
|
Proportion of patients with any grade reduction in reticulin fibrosis
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Pathological Conditions, Anatomical
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Hypertrophy
- Primary Myelofibrosis
- Thrombocytosis
- Thrombocythemia, Essential
- Polycythemia Vera
- Polycythemia
- Splenomegaly
Other Study ID Numbers
- ARD12888
- U1111-1130-3710 (OTHER: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelofibrosis
-
Assaf-Harofeh Medical CenterUnknownMyelofibrosis, Primary | Myelofibrosis, Post PV | Myelofibrosis, Post ETIsrael
-
Centre Hospitalier Annecy GenevoisCompleted
-
AbbVieRecruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
-
AbbVieActive, not recruitingMyelofibrosis (MF)United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
-
AbbVieTerminatedMyelofibrosis (MF)United States, Korea, Republic of, South Africa
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan
-
The University of Hong KongRecruitingMyelofibrosis | Primary Myelofibrosis, Prefibrotic StageHong Kong
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingModerate and High Risk MyelofibrosisChina
-
Telios Pharma, Inc.RecruitingPrimary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET MyelofibrosisSpain, United States, France, Poland, Italy, Germany
Clinical Trials on SAR302503
-
SanofiCompletedHematopoietic NeoplasmUnited States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
SanofiCompletedRenal ImpairmentUnited States
-
SanofiCompletedHepatic ImpairmentUnited States
-
SanofiCompleted
-
SanofiCompletedNeoplasm MalignantBelgium, United States
-
SanofiCompletedMyelofibrosisUnited States
-
SanofiCompletedHematopoietic NeoplasmAustria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
-
SanofiCompletedHematopoietic NeoplasmUnited States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
-
University of WashingtonRecruitingAcute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, UnclassifiableUnited States
-
SanofiCompleted